BrightPath Biotherapeutics Co.Ltd. (JP:4594)
:4594
Want to see JP:4594 full AI Analyst Report?
Total Valuation
BrightPath Biotherapeutics Co.Ltd. has a market cap or net worth of ¥6.25B. The enterprise value is ¥2.94B.
Market Cap¥6.25B
Enterprise Value¥2.94B
Share Statistics
BrightPath Biotherapeutics Co.Ltd. has 138,891,300 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding138,891,300
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
BrightPath Biotherapeutics Co.Ltd.’s return on equity (ROE) is -0.55 and return on invested capital (ROIC) is -53.00%.
Return on Equity (ROE)-0.55
Return on Assets (ROA)-0.50
Return on Invested Capital (ROIC)-53.00%
Return on Capital Employed (ROCE)-0.53
Revenue Per Employee2.00K
Profits Per Employee-31.07M
Employee Count42
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of BrightPath Biotherapeutics Co.Ltd. is ―. BrightPath Biotherapeutics Co.Ltd.’s PEG ratio is 0.34.
PE Ratio―
PS Ratio91636.06
PB Ratio3.25
Price to Fair Value3.25
Price to FCF-5.63
Price to Operating Cash Flow0.00
PEG Ratio0.34
Income Statement
In the last 12 months, BrightPath Biotherapeutics Co.Ltd. had revenue of 84.00K and earned -1.30B in profits. Earnings per share was -11.70.
Revenue84.00K
Gross Profit55.00K
Operating Income-1.29B
Pretax Income-1.30B
Net Income-1.30B
EBITDA-1.30B
Earnings Per Share (EPS)-11.70
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
BrightPath Biotherapeutics Co.Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.00
52-Week Price Change10.00%
50-Day Moving Average57.44
200-Day Moving Average63.65
Relative Strength Index (RSI)33.89
Average Volume (3m)2.78M
Important Dates
BrightPath Biotherapeutics Co.Ltd. upcoming earnings date is Aug 7, 2026, TBA (Confirmed).
Last Earnings DateMay 14, 2026
Next Earnings DateAug 7, 2026
Ex-Dividend Date―
Financial Position
BrightPath Biotherapeutics Co.Ltd. as a current ratio of 15.83, with Debt / Equity ratio of 0.00%
Current Ratio15.83
Quick Ratio15.83
Debt to Market Cap0.00
Net Debt to EBITDA1.67
Interest Coverage Ratio0.00
Taxes
In the past 12 months, BrightPath Biotherapeutics Co.Ltd. has paid 2.42M in taxes.
Income Tax2.42M
Effective Tax Rate>-0.01
Enterprise Valuation
BrightPath Biotherapeutics Co.Ltd. EV to EBITDA ratio is -4.28, with an EV/FCF ratio of -4.06.
EV to Sales65.97K
EV to EBITDA-4.28
EV to Free Cash Flow-4.06
EV to Operating Cash Flow-4.06
Balance Sheet
BrightPath Biotherapeutics Co.Ltd. has ¥1.30B in cash and marketable securities with ¥500.00M in debt, giving a net cash position of ¥796.94M billion.
Cash & Marketable Securities¥1.30B
Total Debt¥500.00M
Net Cash¥796.94M
Net Cash Per Share¥5.74
Tangible Book Value Per Share¥21.23
Margins
Gross margin is 65.48%, with operating margin of -1541666.67%, and net profit margin of -1553513.10%.
Gross Margin65.48%
Operating Margin-1541666.67%
Pretax Margin-1550632.14%
Net Profit Margin-1553513.10%
EBITDA Margin-1541666.67%
EBIT Margin-1541666.67%
Analyst Forecast
The average price target for BrightPath Biotherapeutics Co.Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-92.59%
EPS Growth Forecast18.17%